巨細胞性動脈炎治療薬の世界市場 2024年～2031年

概要

世界の巨細胞性動脈炎治療薬市場は、2023年に9億3,320万米ドルに達し、2024年から2031年の予測期間中に9%のCAGRで成長し、2031年までに18億5,950万米ドルに達すると予想されています。

巨細胞性動脈炎（GCA）または側頭動脈炎は血管炎の一種で、血管の炎症を特徴とするまれな疾患群であり、血流を制限し、重要な臓器や組織を損傷する可能性があります。

GCAはしばしば大動脈や、頭部、腕、脚に向かう大きな分枝に影響を与えます。GCAは50歳以上の成人に最も多くみられる血管炎で、70～80歳が最も多いです。頭痛、顎の痛み、突然の永続的な視力喪失を含む視力の変化や喪失を引き起こすことがあります。

GCAは通常、プレドニゾンなどのグルココルチコイドの大量投与で治療され、時には免疫系を抑制する他の薬物、炎症を抑制する薬物、生物学的製剤などで治療されます。

市場力学：

促進要因

老年人口の増加と心血管障害の有病率の上昇

世界の巨細胞性動脈炎治療薬市場の需要は、複数の要因によって牽引されています。主な要因の1つは、老年人口の増加と心血管障害の有病率の上昇が、巨細胞性動脈炎治療薬市場の成長に寄与していることです。

2022年10月のWHOのデータによると、2030年までに世界の6人に1人が60歳以上の高齢者となります。この時、60歳以上の人口に占める割合は2020年の10億人から14億人に増加します。2050年には、世界の60歳以上の人口は2倍（21億人）になります。

2024年5月のCDCによると、米国では男性、女性、人種・民族を問わず心臓病が死因の第1位であり、37秒に1人が心血管疾患で死亡しています。

さらに、GCAは心血管疾患と密接な関係があります。GCAによる炎症は、大動脈瘤や解離などの合併症を引き起こす可能性があります。心血管障害の有病率が上昇し、特に高齢化が進むにつれて、これらの合併症を管理し、患者の転帰を改善するために、効果的なGCA治療薬に対する需要が高まっています。

さらに、臨床試験数の増加や、提携・協力などの主要企業の戦略が、この市場の成長を促進すると思われます。2024年6月のClinicalTrials.govによると、巨細胞性動脈炎（GCA）患者を対象に、グルココルチコイド漸減レジメンと併用したsecukinumabの有効性と安全性をプラセボと比較する第III相試験が実施されました。

また、2022年2月、Kiniksa Pharmaceuticals, Ltd.とHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.は、KiniksaのARCALYSTとマブリリムマブをアジア太平洋地域で開発・商業化するための戦略的提携を発表しました。関節リウマチおよび巨細胞性動脈炎を対象としたマブリリムマブの第2相臨床試験は、主要評価項目および副次的評価項目を統計学的に有意に達成しました。

阻害要因

高額な治療費、承認された薬剤の限られた入手可能性、個人の認識・診断不足、治療による副作用などの要因が市場を阻害すると予想されます。

本レポートの詳細について- サンプル請求

目次

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 高齢者人口の増加と心血管疾患の有病率の上昇
    • ヘルスケアにおける技術の進歩
  • 抑制要因
    • 治療費の高騰
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 薬剤タイプ別

• 副腎皮質ホルモン剤
• 免疫抑制剤
• 抗凝固剤
• 生物製剤
• その他

第7章 投与経路別

• 経口
• 静脈内投与
• 皮下投与
• その他

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Genentech, Inc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• F. Hoffmann-La Roche Ltd
• Biogen
• Novartis AG
• Aark Pharmaceuticals
• Aetna Inc
• Sartorius AG
• Fresenius Kabi USA
• Bio-Rad Laboratories, Inc
• CELLTRION INC

第12章 付録

Overview

The global giant cell arteritis drugs market reached US$ 933.2 million in 2023 and is expected to reach US$ 1859.5 million by 2031 growing with a CAGR of 9% during the forecast period 2024-2031.

Giant Cell Arteritis (GCA) or temporal arteritis is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues.

It frequently affects the aorta and its large branches to the head, arms, and legs. GCA is the most common form of vasculitis in adults over the age of 50, most commonly between the ages of 70 and 80 years. Women have the highest risk of developing this disease, which can cause headaches, jaw pain, and changes in or loss of vision, including sudden and permanent loss of vision.

GCA is typically treated with high doses of glucocorticoids such as prednisone, and sometimes with other medications that also suppress the immune system, to control inflammation, biologic drugs, and others.

Market Dynamics: Drivers

The growing geriatric population and the rise in the prevalence of cardiovascular disorders

The demand for the global giant cell arteritis drugs market is driven by multiple factors. One of the key factors is the growing geriatric population and the rise in the prevalence of cardiovascular disorders are contributing to the growth of the GCA treatment market.

As per WHO data in October 2022, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion).

According to the CDC in May 2024, heart disease is the leading cause of death among men, women, and people of racial and ethnic groups in the U.S. One person dies every 37 seconds in the country from cardiovascular disease.

Moreover, GCA is closely linked to cardiovascular disorders. The inflammation caused by GCA can lead to complications such as aortic aneurysms and dissections. As the prevalence of cardiovascular disorders rises, particularly in the aging population, the demand for effective GCA drugs increases to manage these complications and improve patient outcomes.

In addition, rising the number of clinical trials and key players' strategies such as partnerships & collaborations would drive this market growth. According to ClinicalTrials.gov in June 2024, a phase III study of the efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA).

Also, in February 2022, Kiniksa Pharmaceuticals, Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., announced a strategic collaboration to develop and commercialize Kiniksa's ARCALYST and mavrilimumab in the Asia Pacific Region. Phase 2 clinical trials of mavrilimumab in rheumatoid arthritis and giant cell arteritis achieved their primary and secondary endpoints with statistical significance.

Restraints

Factors such as the high cost of treatment, limited availability of approved drugs, lack of awareness & diagnosis among individuals, and adverse effects of treatment, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global giant cell arteritis drugs market is segmented based on drug class, route of administration, distribution channel, and region.

The corticosteroids segment accounted for approximately 65.3% of the global giant cell arteritis drugs market share

The corticosteroids segment is expected to hold the largest market share over the forecast period. Owing to these are the most effective and well-tolerated drugs used to manage giant cell arteritis. Corticosteroids are known to reduce inflammation in the walls of arteries affected by giant cell arteritis, as well as suppressing the immune system which can help reduce the symptoms and prevent permanent damage to the arteries.

According to an Ophthalmology research publication in November 2022, corticosteroids (e.g. prednisone, prednisolone, methylprednisolone) have remained the mainstay of treatment for GCA for the past 70 years due to their profound immunosuppressive effects.

Moreover, key players in the industry more focus on the treatment for GCA, rising number of clinical trials and product approvals would drive this segment growth. For instance, in June 2024, HCPLive discussed a phase 3, randomized, placebo-controlled trial that compared 2 doses of upadacitinib versus placebo among a cohort of patients with giant cell arteritis (GCA). The findings, presented at the 2024 European Congress of Rheumatology (EULAR) conference, focused on the first 52-week study period.

Also, in September 2023, Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.

Geographical Analysis

North America accounted for approximately 43.2% of the global giant cell arteritis drugs market share

North America region is expected to hold the largest market share over the forecast period. The rising prevalence of GCA and well-advanced healthcare infrastructure help to drive this market growth.

As per Springer Open research publication in January 2024, the annual incidence of GCA is approximately 15-25 cases per 100,000 persons and nearly exclusively occurs in people over 50 years old. Whilst the incidence of GCA increases with age, it is twice as common in women as men. The lifetime risk of GCA in women is 1% compared to 0.5% in men.

Moreover, government favorable reimbursement policies, increasing R&D investments, and major players in the industry more focus on clinical trials and product launches & approvals would drive this market growth in this region.

For instance, in May 2023, AbbVie announced the results of Phase 2 SLEek study evaluating upadacitinib (RINVOQ 30 mg) alone and in combination [ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg)] in adults with moderately to severely active systemic lupus erythematosus (SLE) who continued to receive standard lupus therapies. The study results are being presented as an oral presentation during the European Congress of Rheumatology, EULAR 2023. Upadacitinib (RINVOQ) is in Phase 3 development for giant cell arteritis, Takayasu arteritis, and systemic lupus erythematosus

Also, in April 2024, Fresenius Kabi announced the immediate U.S. availability of Tyenne (tocilizumab-aazg), a biosimilar of Actemra (tocilizumab). Biologic medicine is indicated for the treatment of several autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Market Segmentation

By Drug Class

• Corticosteroids
• Immune-suppressing Agents
• Anti Coagulants
• Biologics
• Others

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the giant cell arteritis drugs market include Genentech, Inc., F. Hoffmann-La Roche Ltd, Biogen, Novartis AG, Aark Pharmaceuticals, Aetna Inc., Sartorius AG, Fresenius Kabi USA, Bio-Rad Laboratories, Inc and CELLTRION INC among others.

Key Developments

• In April 2024, AbbVie announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA)
• In March 2023, EULAR, Tocilizumab was recommended for new, relapsing giant cell arteritis. Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.

Why Purchase the Report?

• To visualize the global giant cell arteritis drugs market segmentation based on drug class, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of giant cell arteritis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global giant cell arteritis drugs market report would provide approximately 62 tables, 55 figures, and 183 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing Geriatric Population and the Rise in the Prevalence of Cardiovascular Disorders
    • 4.1.1.2. Technological Advancements in Healthcare
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Drug Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 6.1.2. Market Attractiveness Index, By Drug Type
• 6.2. Corticosteroids
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Immune-suppressing Agents
• 6.4. Anti Coagulants
• 6.5. Biologics
• 6.6. Others

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Intravenous
• 7.4. Subcutaneous
• 7.5. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Genentech, Inc *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. F. Hoffmann-La Roche Ltd
• 11.3. Biogen
• 11.4. Novartis AG
• 11.5. Aark Pharmaceuticals
• 11.6. Aetna Inc
• 11.7. Sartorius AG
• 11.8. Fresenius Kabi USA
• 11.9. Bio-Rad Laboratories, Inc
• 11.10. CELLTRION INC

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us